Anavex Life Sciences Corp (AVXL)

[12x]

The institution holding hasn’t changed much during the quarter. The only 4 over 1% holders (vanguard, Blackrock, state street, and Geneos) are steady. Among the near 1% holders, Goldman exited and BOA, Nwum and Susquehanna entered.

Missling has 500,000 options expiring in early July. He has next week to make a decision on that option before the blackout period trading restrictions takes effect. There has been no insider buying after the announcement of the “successful AD p2b/3 trial”. Missling can make the statement here not just empty words: excise and own that 500,000 shares. Become the largest individual share holder and lead the sigma-1 CNS treatment revolution.

Or is he going to continue to stay in the shadow of the 140 million cash and counting pennies: not willing to spend that $50k to hire a junior SAS programmer to report trial TLD a little faster, not willing to spend the $400k to hire the head R&D to address organizational deficiency, not willing to start any rare disease trial, not willing to starting us based PD trials, … 6 month after announcing “the successful AD p2b/3 trial”…